Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

Protection induced by malaria virus-like particles containing codon-optimized AMA-1 of Plasmodium berghei.

Lee DH, Chu KB, Kang HJ, Lee SH, Chopra M, Choi HJ, Moon EK, Inn KS, Quan FS.

Malar J. 2019 Dec 3;18(1):394. doi: 10.1186/s12936-019-3017-2.

2.

Influenza Virus-Like Particles Presenting both Toxoplasma gondii ROP4 and ROP13 Enhance Protection against T. gondii Infection.

Kang HJ, Lee SH, Kim MJ, Chu KB, Lee DH, Chopra M, Choi HJ, Park H, Jin H, Quan FS.

Pharmaceutics. 2019 Jul 16;11(7). pii: E342. doi: 10.3390/pharmaceutics11070342.

3.

Co-Delivery of M2e Virus-Like Particles with Influenza Split Vaccine to the Skin Using Microneedles Enhances the Efficacy of Cross Protection.

Kim MC, Kim KH, Lee JW, Lee YN, Choi HJ, Jung YJ, Kim YJ, Compans RW, Prausnitz MR, Kang SM.

Pharmaceutics. 2019 Apr 18;11(4). pii: E188. doi: 10.3390/pharmaceutics11040188.

4.

Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals.

Homayun B, Lin X, Choi HJ.

Pharmaceutics. 2019 Mar 19;11(3). pii: E129. doi: 10.3390/pharmaceutics11030129. Review.

5.

Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus.

Kim KH, Kwon YM, Lee YT, Kim MC, Hwang HS, Ko EJ, Lee Y, Choi HJ, Kang SM.

Vaccines (Basel). 2018 Sep 20;6(4). pii: E66. doi: 10.3390/vaccines6040066.

6.

Macropored microparticles with a core-shell architecture for oral delivery of biopharmaceuticals.

Homayun B, Kumar A, Nascimento PTH, Choi HJ.

Arch Pharm Res. 2018 Aug;41(8):848-860. doi: 10.1007/s12272-018-1062-y. Epub 2018 Aug 9.

PMID:
30094582
7.

Facile fabrication of microparticles with pH-responsive macropores for small intestine targeted drug formulation.

Homayun B, Sun C, Kumar A, Montemagno C, Choi HJ.

Eur J Pharm Biopharm. 2018 Jul;128:316-326. doi: 10.1016/j.ejpb.2018.05.014. Epub 2018 May 16.

8.

Antioxidant-based synergistic eradication of methicillin-resistant Staphylococcus aureus (MRSA) biofilms with bacitracin.

Oh E, Bae J, Kumar A, Choi HJ, Jeon B.

Int J Antimicrob Agents. 2018 Jul;52(1):96-99. doi: 10.1016/j.ijantimicag.2018.03.006. Epub 2018 Mar 19.

PMID:
29567095
9.

Protection induced by virus-like particle vaccine containing tandem repeat gene of respiratory syncytial virus G protein.

Kim AR, Lee DH, Lee SH, Rubino I, Choi HJ, Quan FS.

PLoS One. 2018 Jan 16;13(1):e0191277. doi: 10.1371/journal.pone.0191277. eCollection 2018.

10.

Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate.

Kim MC, Lee YN, Kim YJ, Choi HJ, Kim KH, Lee YJ, Kang SM.

Antiviral Res. 2017 Dec;148:43-52. doi: 10.1016/j.antiviral.2017.10.018. Epub 2017 Oct 26.

11.

Microfabrication for Drug Delivery.

Koch B, Rubino I, Quan FS, Yoo B, Choi HJ.

Materials (Basel). 2016 Aug 1;9(8). pii: E646. doi: 10.3390/ma9080646. Review.

12.

Respiratory Protection against Pandemic and Epidemic Diseases.

Rubino I, Choi HJ.

Trends Biotechnol. 2017 Oct;35(10):907-910. doi: 10.1016/j.tibtech.2017.06.005. Epub 2017 Jul 18.

PMID:
28733078
13.

Smart Microparticles with a pH-responsive Macropore for Targeted Oral Drug Delivery.

Kumar A, Montemagno C, Choi HJ.

Sci Rep. 2017 Jun 8;7(1):3059. doi: 10.1038/s41598-017-03259-x.

14.

Protection induced by virus-like particles containing Toxoplasma gondii microneme protein 8 against highly virulent RH strain of Toxoplasma gondii infection.

Lee SH, Kim AR, Lee DH, Rubino I, Choi HJ, Quan FS.

PLoS One. 2017 Apr 13;12(4):e0175644. doi: 10.1371/journal.pone.0175644. eCollection 2017.

15.

Universal and reusable virus deactivation system for respiratory protection.

Quan FS, Rubino I, Lee SH, Koch B, Choi HJ.

Sci Rep. 2017 Jan 4;7:39956. doi: 10.1038/srep39956.

16.

Microneedle delivery of trivalent influenza vaccine to the skin induces long-term cross-protection.

Kim YC, Lee SH, Choi WH, Choi HJ, Goo TW, Lee JH, Quan FS.

J Drug Target. 2016 Dec;24(10):943-951. doi: 10.3109/1061186X.2016.1159213. Epub 2016 Mar 27.

PMID:
26957023
17.

Effect of Osmotic Pressure on the Stability of Whole Inactivated Influenza Vaccine for Coating on Microneedles.

Choi HJ, Song JM, Bondy BJ, Compans RW, Kang SM, Prausnitz MR.

PLoS One. 2015 Jul 31;10(7):e0134431. doi: 10.1371/journal.pone.0134431. eCollection 2015.

18.

Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.

Kim MC, Lee JW, Choi HJ, Lee YN, Hwang HS, Lee J, Kim C, Lee JS, Montemagno C, Prausnitz MR, Kang SM.

J Control Release. 2015 Jul 28;210:208-16. doi: 10.1016/j.jconrel.2015.05.278. Epub 2015 May 21.

19.

Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses.

Patel JM, Kim MC, Vartabedian VF, Lee YN, He S, Song JM, Choi HJ, Yamanaka S, Amaram N, Lukacher A, Montemagno CD, Compans RW, Kang SM, Selvaraj P.

Nanomedicine. 2015 Jul;11(5):1097-107. doi: 10.1016/j.nano.2015.02.008. Epub 2015 Mar 6.

20.

Recent Progress in Advanced Nanobiological Materials for Energy and Environmental Applications.

Choi HJ, Montemagno CD.

Materials (Basel). 2013 Dec 11;6(12):5821-5856. doi: 10.3390/ma6125821. Review.

Supplemental Content

Loading ...
Support Center